Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Financing › Details

Aelin Therapeutics–Novartis: investment, 201712 financing round Series A totalling €27m incl investor Novartis Venture Fund

 

Period Period 2017-12-11
Organisations Money taker Aelin Therapeutics (BE)
  Money source Novartis Venture Fund (NVF)
  Group Novartis (Group)
Products Product Pept-in™ protein knockdown technology
  Product 2 venture capital
Index term Index term Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+
     

VIB, Flanders Interuniversity Institute of Biotechnology. (12/11/17). "Press Release: New VIB Start-up Aelin Therapeutics Secures 27m € to Exploit Its Proprietary Pept-in Protein Knockdown Platform".

Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a 27 M€ investment to pioneer a novel modality in drug development in order to create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology, branded Pept-ins™, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The company will use the proceeds of the 27 M€ Series A financing, to bring a first Pept-in product to the clinic.
 
Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches.
 
Building on the solid science and a convincing data set, Aelin Therapeutics has succeeded in raising 27 M€, bringing together a strong group of well-reputed investors consisting of LSP (the Netherlands), PMV (Belgium), Novartis Venture Fund (Switzerland), Boehringer Ingelheim Venture Fund (Germany) and Fund+ (Belgium). These resources enable the company to build on its platform capabilities and develop its first products until the end of initial clinical development.




Scientific publications
De novo design of a biologically active amyloid, Gallardo et al., Science 2016
Protein aggregation as an antibiotic design strategy, Bednarska N et al., Molecular Microbiology 2016

   
Record changed: 2017-12-19

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Aelin Therapeutics (BE)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top